270 related articles for article (PubMed ID: 31670987)
1. Why hasn't there been more progress in new Chagas disease drug discovery?
Vermelho AB; Rodrigues GC; Supuran CT
Expert Opin Drug Discov; 2020 Feb; 15(2):145-158. PubMed ID: 31670987
[No Abstract] [Full Text] [Related]
2. Drug discovery for chagas disease: A viewpoint.
Kratz JM
Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
[TBL] [Abstract][Full Text] [Related]
3. New drug discovery strategies for the treatment of benznidazole-resistance in
Murta SMF; Lemos Santana PA; Jacques Dit Lapierre TJW; Penteado AB; El Hajje M; Navarro Vinha TC; Liarte DB; de Souza ML; Goulart Trossini GH; de Oliveira Rezende Júnior C; de Oliveira RB; Ferreira RS
Expert Opin Drug Discov; 2024 Jun; 19(6):741-753. PubMed ID: 38715393
[TBL] [Abstract][Full Text] [Related]
4. Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status.
Torchelsen FKVDS; Mazzeti AL; Mosqueira VCF
Expert Opin Investig Drugs; 2024 Jun; 33(6):575-590. PubMed ID: 38686546
[TBL] [Abstract][Full Text] [Related]
5. Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?
Martínez-Peinado N; Cortes-Serra N; Losada-Galvan I; Alonso-Vega C; Urbina JA; Rodríguez A; VandeBerg JL; Pinazo MJ; Gascon J; Alonso-Padilla J
Expert Opin Investig Drugs; 2020 Sep; 29(9):947-959. PubMed ID: 32635780
[TBL] [Abstract][Full Text] [Related]
6. New drugs for neglected infectious diseases: Chagas' disease.
Machado FS; Tanowitz HB; Teixeira MM
Br J Pharmacol; 2010 May; 160(2):258-9. PubMed ID: 20423339
[TBL] [Abstract][Full Text] [Related]
7. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
8. Challenges in Chagas Disease Drug Discovery: A Review.
Paucar R; Moreno-Viguri E; Pérez-Silanes S
Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
[TBL] [Abstract][Full Text] [Related]
9. Animal models of Chagas disease and their translational value to drug development.
Chatelain E; Scandale I
Expert Opin Drug Discov; 2020 Dec; 15(12):1381-1402. PubMed ID: 32812830
[TBL] [Abstract][Full Text] [Related]
10. Chagas Disease: Current View of an Ancient and Global Chemotherapy Challenge.
Martín-Escolano J; Medina-Carmona E; Martín-Escolano R
ACS Infect Dis; 2020 Nov; 6(11):2830-2843. PubMed ID: 33034192
[TBL] [Abstract][Full Text] [Related]
11. Fexinidazole: a potential new drug candidate for Chagas disease.
Bahia MT; de Andrade IM; Martins TA; do Nascimento ÁF; Diniz Lde F; Caldas IS; Talvani A; Trunz BB; Torreele E; Ribeiro I
PLoS Negl Trop Dis; 2012; 6(11):e1870. PubMed ID: 23133682
[TBL] [Abstract][Full Text] [Related]
12. Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015).
Rodriguez JB; Falcone BN; Szajnman SH
Expert Opin Ther Pat; 2016 Sep; 26(9):993-1015. PubMed ID: 27376456
[TBL] [Abstract][Full Text] [Related]
13. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
14.
de Araujo FF; Nagarkatti R; Mazzeti AL; Gonçalves KR; de Figueiredo Diniz L; Campos do Vale I; Martins-Filho OA; Debrabant A; Bahia MT; Teixeira-Carvalho A
Front Immunol; 2023; 14():1340755. PubMed ID: 38283347
[TBL] [Abstract][Full Text] [Related]
15. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic screening approaches for Chagas disease drug discovery.
Chatelain E; Ioset JR
Expert Opin Drug Discov; 2018 Feb; 13(2):141-153. PubMed ID: 29235363
[TBL] [Abstract][Full Text] [Related]
17. Novel drug discovery for Chagas disease.
Moraes CB; Franco CH
Expert Opin Drug Discov; 2016; 11(5):447-55. PubMed ID: 26967915
[TBL] [Abstract][Full Text] [Related]
18. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
19. Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery.
Ekins S; de Siqueira-Neto JL; McCall LI; Sarker M; Yadav M; Ponder EL; Kallel EA; Kellar D; Chen S; Arkin M; Bunin BA; McKerrow JH; Talcott C
PLoS Negl Trop Dis; 2015; 9(6):e0003878. PubMed ID: 26114876
[TBL] [Abstract][Full Text] [Related]
20. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
Moraes CB; Giardini MA; Kim H; Franco CH; Araujo-Junior AM; Schenkman S; Chatelain E; Freitas-Junior LH
Sci Rep; 2014 Apr; 4():4703. PubMed ID: 24736467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
